+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies

Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies

Biochemical and Biophysical Research Communications 232(2): 367-372

The tumor antigen 90K (Mac-2BP, L3 antigen), which has been shown to have T cell costimulatory activity, is a approximately 90 kDa secreted protein found in high levels in plasma, saliva, breast milk and other human fluids. The 90K antigen can be divided into three domains: an amino terminal scavenger receptor cysteine-rich (SRCR)-like domain (D1), followed by a heavily glycosylated mucin-like domain (D2) and a approximately 27 kDa carboxy-terminal domain (D3). In this study we report on the construction of six different 90K immunoglobulin (Ig) fusion proteins containing different 90K domain combinations. Initially these fusion proteins were used to identify which 90K domain contains the epitopes recognized by the anti-90K monoclonal antibodies (mAb) SP2 and L3. Both of these mAbs were found to recognize 90K-D2. A new panel of anti-90K mAb was then generated by immunizing mice with ascites derived 90K protein. The 90K domain specific fusion proteins were then used to identify novel anti-90K mAbs which recognize the amino terminal SRCR domain and the carboxy terminal approximately 27 kDa domain of 90K. Two novel anti-90K SRCR (D1) and one anti-90 27 kDa domain (D3) mAbs were obtained. These 90K-Ig fusion proteins, as well as the novel and existing anti-90K mAbs, provide a set of tools which will allow further dissection of the structure and function of this immune modulatory protein.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 008811492

Download citation: RISBibTeXText

PMID: 9125183

DOI: 10.1006/bbrc.1997.6258

Related references

Syngeneic anti idiotypic monoclonal antibodies to murine anti human high molecular weight melanoma associated antigen hmw maa monoclonal antibodies immunochemical characterization and clinical applications. Tumor Biology 8(6): 343, 1987

Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. Journal of Immunology 143(11): 3844-3852, 1989

Studies on the generation and application of monoclonal antibodies against tumor marker antigen i. production and characterization of monoclonal antibodies against placental alkaline phosphatase. Korean Journal of Zoology 31(4): 300-308, 1988

Monoclonal anti-idiotopic antibodies against myasthenia-inducing anti-acetylcholine receptor monoclonal antibodies. Preponderance of nonparatope-directed antibodies affecting antigen binding. Journal of Immunology 140(1): 62-68, 1988

Detection of circulating tumor-associated antigen depends on the domains recognized by the monoclonal antibodies used: N-terminal trimmed EpCAM-levels are much higher than untrimmed forms. Immunology Letters 143(2): 184-192, 2012

Studies of monoclonal antibodies specific for major histocompatibility complex products of the rat. III. Production and characterization of syngeneic and allogeneic monoclonal anti-idiotypic antibodies to monoclonal alloantibodies. Scandinavian Journal of Immunology 21(6): 575-584, 1985

Tumor unique antigens on t cell chronic lymphatic leukemia t cll recognized by monoclonal antibodies treatment of t cll with anti idiotypic monoclonal antibody. Metzgar, R S And M S Mitchell (Ed ) Ucla (University Of California-Los Angeles) Symposia on Molecular And Cellular Biology New Series, Vol 99 Human Tumor Antigens And Specific Tumor Therapy; Keystone, Colorado, Usa, April 23-30, Xix+366p Alan R Liss, Inc : New York, New York, Usa Illus 277-286, 1988

Studies on the differentiation of T lymphocytes in sheep. III. Preliminary characterization of an antigen recognized by two anti-pan T-cell monoclonal antibodies. Immunology 58(1): 71-77, 1986

Identification and characterization of tau phosphopeptide epitopes recognized by anti-paired helical filament monoclonal antibodies. Society for Neuroscience Abstracts 22(1-3): 975, 1996

Characterization of antigens recognized by chimeric tumor necrosis treatment anti-nuclear monoclonal antibodies. Proceedings of the American Association for Cancer Research Annual Meeting 43: 912-913, 2002

Studies on murine ige with monoclonal antibodies i. characterization of rat monoclonal anti ige antibodies and the use of these antibodies for determinations of serum ige levels and for anaphylactic reactions. International Archives of Allergy and Applied Immunology 85(1): 47-54, 1988

Syngeneic polyclonal and monoclonal antiidiotypic antibodies to murine anti human high molecular weight melanoma associated antigen and anti hla monoclonal antibodies. Kano, K , Et Al (Ed ) Cellular, Molecular And Genetic Approaches to Immunodiagnosis And Immunotherapy; Viiith International Conference on Labeled Antibodies, Tokyo, Japan, November 5-7, 1985 Xv+509p S Karger Ag: Basel, Switzerland; New York, New York, Usa Illus 251-258, 1987

Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. Journal of Immunology 166(8): 5271-5278, 2001

Preparation of monoclonal antibodies against duck hepatitis B core antigen and analysis of the monoclonal antibodies. Uirusu 39(1): 55-60, 1989

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Design Development and Therapy 12: 981-986, 2018